TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16240065
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation group.
Study: 29185780
Drug: Saffron capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron capsules (15 mg/twice daily)
Study: 23926422
Drug: Quetiapine (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (25-100 mg/day, mean 67.6 mg/day)
Study: 23926422
Drug: Haloperidol (0.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5-2.0 mg/day, mean 0.8 mg/day)
Study: 17198445
Drug: Pulse intravenous
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse intravenous methylprednisolone (1000 mg for 4 days) plus cyclophosphamide (500 mg for 1 day)
Study: 17198445
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1-2 mg/kg/day for 28 days) plus azathioprine (1.5 mg/kg/day)
Study: 12749513
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg QD for 5 days
Study: 12749513
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2 to 5
Study: 1316079
Drug: Once-daily 400
Normalized name: eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 400 mg lomefloxacin
Study: 1316079
Drug: Twice-daily 400
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily 400 mg lomefloxacin
Study: 2931232
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg once a day)
Study: 2931232
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet once a day)
Study: 24854041
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump (continuous subcutaneous insulin infusion [CSII])
Study: 21781200
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing exercise (twice daily for 5 minutes over 4 weeks)
Study: 18626263
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of 1% testosterone gel (Testogel)
Study: 16034518
Drug: Rebeccamycin analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebeccamycin analogue (RA) 500 mg/m(2) as a 1 hr infusion repeated every 3 weeks (Arm A)
Study: 16034518
Drug: Rebeccamycin analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebeccamycin analogue (RA) 140 mg/m(2)/day x 5 days repeated every 3 weeks (Arm B)
Study: 10539878
Drug: Preoperative transfusion
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative transfusion regimen (conservative to bring hemoglobin concentration to between 9 and 11 g/dl)
Study: 8955454
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nalidixic acid and metronidazole
Study: 31991898
Drug: High-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega-3 and omega-6 fatty acids supplementation with antioxidant vitamins (20 mL containing 810 mg Eicosapentaenoic acid, 4140 mg Docosahexaenoic acid, 1800 mg gamma-Linolenic acid, 3150 mg Linoleic acid, 0.6 mg vitamin A, 22 mg vitamin E, 760 mg pure γ-tocopherol)
Study: 28986051
Drug: Intravenous 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.2 mg/kg dexamethasone (group D)
Study: 25060792
Drug: Polyphenol-rich olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich olive oil (366 mg/kg)
Study: 25060792
Drug: Polyphenol-poor olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-poor olive oil (2.7 mg/kg)
Study: 11270012
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl administered 15 min before surgery (group I)
Study: 11270012
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl administered 15 min before waking at the end of the operation (group II)
Study: 9509205
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg.kg‐1
Study: 9509205
Drug: Thiopentone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 1.0 mg.kg‐1
Study: 7830998
Drug: C3F8, SF6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: C3F8, SF6, silicone oil as postoperative tamponading agents
Study: 2905250
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate 150 mg daily at 9 pm for 14 days
Study: 30121609
Drug: Triple pill
Normalized name: Triple Wormer Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple pill (fixed low-dose combination of three antihypertensive drugs)
Study: 26253237
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (supported self-management and standard treatment)
Study: 18281242
Drug: Pre-ovulatory pertubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ovulatory pertubation with low-dose lignocaine
Study: 16532491
Drug: Glycoprotein (GP)
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein (GP) IIb/IIIa inhibitors
Study: 12649057
Drug: Cognitive-behavioral smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral smoking cessation treatment plus moderate-intensity physical activity
Study: 11573317
Drug: Sting-Aid (aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sting-Aid (aluminum sulfate solution)
Study: 8139627
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no epoetin treatment)
Study: 26169781
Drug: Prenatal oral
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal oral vitamin D3 supplementation (4200 IU/wk)
Study: 26169781
Drug: Prenatal oral
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal oral vitamin D3 supplementation (16,800 IU/wk)
Study: 26169781
Drug: Prenatal oral
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal oral vitamin D3 supplementation (28,000 IU/wk)
Study: 26169781
Drug: Postpartum oral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postpartum oral vitamin D3 supplementation (28,000 IU/wk)
Study: 23454404
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg desmopressin orally disintegrating tablet once daily
Study: 21570355
Drug: MRKAd5 HIV‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRKAd5 HIV‐1 vaccine
Study: 16339157
Drug: Digoxin at
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin at SDC 0.5-0.9 ng/mL
Study: 16339157
Drug: Digoxin at
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin at SDC >=1.0 ng/mL
Study: 11132321
Drug: Recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant growth hormone (rGH) administered subcutaneously at a dose of 0.5 lU/kg per day for 28 days
Study: 11132321
Drug: Recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant growth hormone (rGH)
Study: 26325557
Drug: Finerenone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 7.5 mg/d
Study: 26325557
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg/d
Study: 26325557
Drug: Finerenone 15
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Finerenone 15 mg/d
Study: 26325557
Drug: Finerenone 20
Normalized name: finerenone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 20 mg/d
Study: 21527115
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + pioglitazone
Study: 21527115
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + glimepiride
Study: 18958842
Drug: glimepiride (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride (3 mg daily)
Study: 12663295
Drug: Oligofructose-supplemented cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose-supplemented cereal (0.55 g/15 g cereal)
Study: 12663295
Drug: Cereal fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal fortified with zinc (1 mg/15 g cereal)
Study: 8633815
Drug: Nevirapine, zidovudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine, zidovudine, and didanosine (triple-combination regimen)
Study: 8633815
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and didanosine (double-combination regimen)
Study: 31930222
Drug: DIVER‐100® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIVER‐100® (2 capsules/day for 10 days per month, for 3 months)
Study: 29554535
Drug: escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram (10 mg twice/day) + CBX (200 mg twice/day)
Study: 29554535
Drug: escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram (10 mg twice/day) + placebo (twice/day)
Study: 24560438
Drug: Memantine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 40 mg
Study: 22234683
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 100 mg twice daily
Study: 22234683
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 200 mg once daily
Study: 22234683
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin 100 mg once daily
Study: 15209959
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 30 mg b.i.d.
Study: 15209959
Drug: Fexofenadine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (any dose)
Study: 15209959
Drug: Any fexofenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any fexofenadine doses
Study: 11260249
Drug: Doxepin cream
Normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin cream (5%) applied 4 times daily for 3 days
Study: 11260249
Drug: Basic ointment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic ointment (control) applied 4 times daily for 3 days
Study: 8047334
Drug: Spray application
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray application of 1% cyclopentolate hydrochloride
Study: 8047334
Drug: Spray application
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray application of cyclopentolate hydrochloride
Study: 30888330
Drug: tablet+messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet+messages
Study: 30888330
Drug: tablet only
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet only
Study: 28718233
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of 0.5% hyperbaric bupivacaine (Group A)
Study: 28718233
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of 0.5% hyperbaric bupivacaine (Group B)
Study: 23561946
Drug: Doxepin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (10 mg daily)
Study: 23561946
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy with bright light therapy
Study: 19549691
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg bid the day before and the day of the procedure plus saline i.v. 0.9% 1 ml/kg/h 12-24 h before and 24 h after the procedure)
Study: 16700815
Drug: New insoluble-matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: New insoluble-matrix retropalpebral ophthalmic insert containing 5.38 mg phenylephrine and 0.28 mg tropicamide
Study: 16700815
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (insert and eye drops)
Study: 16700815
Drug: New insoluble-matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: New insoluble-matrix retropalpebral ophthalmic insert
Study: 10960643
Drug: Dinoprostone 0.5
Normalized name: dinoprostone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone 0.5 mg every 6 hours (maximum four doses)
Study: 8985996
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (Methenamine)
Study: 8985996
Drug: Solution B
Normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution B (blank solution)
Study: 1462902
Drug: Lidocaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (100 mg intravenous bolus followed by 300 mg intramuscular injection)
Study: 3913425
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nicergoline (Sermion) daily for 180 days
Study: 3913425
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg dihydroergotamine mesilate (DHETM) daily for 180 days
Study: 19709504
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n = 10)
Study: 12774159
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (1 mmol/kg)
Study: 9512843
Drug: Prophylactic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic epidural blood patch (PEBP) recommended by 37% of centres; more common in US than Canadian centres.
Study: 9512843
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch (EBP) offered most commonly at or within 24 hours of diagnosis of post-dural puncture headache (PDPH).
Study: 23998910
Drug: Isoflavone intake
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone intake (highest quartile Q4: 1.6‐78.8 mg/d)
Study: 8159835
Drug: sulbactam/ampicillin 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbactam/ampicillin 1 g IV before surgical incision and then 8-hourly x 3 days
Study: 8159835
Drug: cefuroxime 2
Normalized name: cefuroxime 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefuroxime 2 g IV before surgical incision and then 8-hourly x 3 days
Study: 1683196
Drug: Chromium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium supplementation (600 micrograms daily divided into three doses)
Study: 6749826
Drug: Amitriptyline-perphenazine (100/8-150/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline-perphenazine (100/8-150/12 mg/day)
Study: 6749826
Drug: Doxepin (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (100-150 mg/day)
Study: 29075343
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 mL over seven days followed by 10 mL until day 30)
Study: 25359354
Drug: Immediate isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate isoniazid treatment
Study: 25359354
Drug: Deferred isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred isoniazid treatment
Study: 17072689
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol/remifentanil/rocuronium (TIVA)
Study: 10618560
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (goal dose 100 microgram/min)
Study: 8939149
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg zileuton
Study: 8939149
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg zileuton
Study: 29878939
Drug: Personalized fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized fluid therapy using noninvasive cardiac output (Clearsight system) monitor
Study: 29878939
Drug: Protocolized fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized fluid therapy approach
Study: 27052531
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 400 μg/d
Study: 27052531
Drug: Creatine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine plus Folic Acid 400 μg/d
Study: 24314907
Drug: Small SZ
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small SZ subgroup not receiving antipsychotic medication (n=10)
Study: 22425936
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (TTM tailored interventions)
Study: 20061906
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg monthly intramuscular octreotide
Study: 11535320
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine administered by needle-free jet injector (JI)
Study: 11535320
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine administered by one JI device
Study: 11535320
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine administered by needle and syringe (N&S)
Study: 9716243
Drug: Propentofylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propentofylline (300 mg t.i.d. taken 1 h before meals)
Study: 8142094
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac 30 mg loading dose followed by IV ketorolac 15 mg every 6 hours (Group 2)
Study: 8142094
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac 60 mg loading dose followed by IV ketorolac 30 mg every 6 hours (Group 3)
Study: 3045341
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (20 mcg)
Study: 3045341
Drug: Papaverine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (7.5 mg) plus Phentolamine (0.25 mg)
Study: 21552726
Drug: Direct and
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct and indirect intervention (Therapy Group - TG)
Study: 16542657
Drug: 125 mL
Normalized name: 125 ML argatroban 1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL intravenous fluid per hour
Study: 16542657
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL intravenous fluid per hour
Study: 10352088
Drug: Omeprazole 2
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 2 x 20 mg/day for 7 days (group A)
Study: 10352088
Drug: Omeprazole 2
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 2 x 40 mg/day for 7 days (group B)
Study: 10352088
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups continued treatment with omeprazole (40 mg/day days 8-14 and 20 mg/day days 15-28)
Study: 29807102
Drug: Subetta add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subetta add-on therapy
Study: 25503168
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg or 20 mg of melatonin
Study: 16404981
Drug: IRS 19
Normalized name: irsogladine
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS 19 vaccine
Study: 10551433
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa receptor antagonists (parenteral formulations)
Study: 8607684
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (20,000 kIU/kg [2.8 mg/kg])
Study: 1934206
Drug: Atracurium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.3 mg.kg‐1 (ED95)
Study: 1934206
Drug: d-tubocurarine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine 0.3 mg.kg‐1 (ED90)
Study: 18330955
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E therapy (Group 3)
Study: 15511602
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen preparation composed of 17-beta estradiol
Study: 1761453
Drug: Cefprozil, 500
Normalized name: Cefprozil, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil, 500 mg once a day
Study: 1761453
Drug: Cefaclor, 250
Normalized name: Cefaclor, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, 250 mg three times a day
Study: 6282790
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) plus high dose CAV, methotrexate and leucovorin
Study: 28489320
Drug: Aspirin (COX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (COX inhibition)
Study: 15054441
Drug: Instant coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant coffee (5 g, approximately 50 mg trigonelline)
Study: 15054441
Drug: Trigonelline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigonelline (50 mg)
Study: 11166143
Drug: Conventional-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose therapy